SIG-003 (Sigilon Therapeutics)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameSIG-003 (Sigilon Therapeutics)
Drug Alias Namehemophilia Cell therapy (Sigilon Therapeutics)encapsulated gene modified allogeneic cells (Sigilon Therapeutics)
ClassificationCell and gene therapy > Cell therapy
Mechanisms of ActionCoagulation factor IX stimulants
TargetsCoagulation factor IX
Therapy Area/IndicationsHemophilia B
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSigilon Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSigilon Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsHemophilia B

Other Information

ATC CodeN/A
Related LinksN/A